Can a Growth Hormone-Releasing Peptide Improve Thinking Skills in Older Adults?
Daily injections of the GHRH analog tesamorelin for 20 weeks improved cognitive function — especially executive function — in both healthy older adults and those with mild cognitive impairment.
Quick Facts
What This Study Found
Twenty weeks of daily GHRH (tesamorelin) injections improved cognitive function in both healthy older adults and those with mild cognitive impairment. The effect was statistically significant in the intent-to-treat analysis (P=.03) and even stronger among those who completed the full protocol (P=.002).
The cognitive benefit was most pronounced for executive function (P=.005), which includes skills like planning, mental flexibility, and multitasking. There was also a trend toward improvement in verbal memory (P=.08). The treatment boosted IGF-1 levels by 117% while keeping them within the normal physiological range, and reduced body fat by 7.4%. In adults with MCI, fasting insulin rose by 35% but remained within normal limits. Adverse events were mild, reported by 68% of those on GHRH versus 36% on placebo.
Key Numbers
n=152 · 20-week treatment · cognition improved P=.03 (ITT), P=.002 (completers) · executive function P=.005 · IGF-1 increased 117% · body fat reduced 7.4% · fasting insulin up 35% in MCI group
How They Did This
This was a randomized, double-blind, placebo-controlled trial conducted at the University of Washington. A total of 152 adults aged 55–87 (66 with MCI, 86 healthy) self-administered daily subcutaneous injections of tesamorelin (1 mg/day) or placebo at bedtime for 20 weeks. Cognitive testing was done at baseline, weeks 10 and 20, and after a 10-week washout period. The battery included tests for executive function, verbal memory, and visual memory. Blood work and body composition scans were also performed.
Why This Research Matters
As people age, levels of GHRH, growth hormone, and IGF-1 naturally decline — and this decline is thought to contribute to cognitive deterioration and possibly Alzheimer's disease. This trial suggests that restoring GHRH signaling with a stabilized analog can meaningfully improve thinking skills in older adults, including those already showing early signs of cognitive decline. If confirmed in longer trials, this peptide-based approach could represent a new strategy for protecting brain health during aging.
The Bigger Picture
Growth hormone and its related signaling molecules decline substantially with age, and there is growing evidence linking this decline to cognitive deterioration and Alzheimer's disease. This trial adds to a small but promising body of research suggesting that restoring GHRH signaling could protect brain health in aging. If longer trials confirm these findings, peptide-based hormonal interventions could become part of preventive cognitive care for older adults.
What This Study Doesn't Tell Us
The 20-week treatment period was relatively short for evaluating long-term brain health effects. The study did not assess whether cognitive benefits persisted after the 10-week washout. Sample size, while reasonable for a controlled trial, was modest, especially when split between MCI and healthy subgroups. The study used tesamorelin, a stabilized GHRH analog, so results may not generalize to other GHRH-related peptides. Adverse events were mild but more common in the treatment group.
Questions This Raises
- ?Do the cognitive benefits persist after treatment is stopped, or do they fade during washout?
- ?Would longer treatment durations produce larger or more durable cognitive improvements?
- ?Could GHRH-based therapies delay or prevent progression from mild cognitive impairment to Alzheimer's disease?
Trust & Context
- Key Stat:
- P = .002 Significance level for cognitive improvement in adults who completed the full 20-week GHRH treatment protocol
- Evidence Grade:
- This is a randomized, double-blind, placebo-controlled trial — the gold standard for clinical research — with 152 participants and statistically significant results. The study design, sample size, and clear methodology justify a 'Strong' evidence grade.
- Study Age:
- Published in 2012, this study is over a decade old. However, its findings remain relevant as one of the few well-designed RCTs examining GHRH's effects on cognition. More recent follow-up research has continued to explore this relationship.
- Original Title:
- Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.
- Published In:
- Archives of neurology, 69(11), 1420-9 (2012)
- Authors:
- Baker, Laura D, Barsness, Suzanne M, Borson, Soo, Merriam, George R, Friedman, Seth D, Craft, Suzanne, Vitiello, Michael V
- Database ID:
- RPEP-01900
Evidence Hierarchy
Frequently Asked Questions
What is tesamorelin and how does it relate to growth hormone?
Tesamorelin is a stabilized synthetic version of growth hormone-releasing hormone (GHRH). Rather than providing growth hormone directly, it signals your pituitary gland to produce and release more of its own growth hormone naturally. It is FDA-approved for reducing excess belly fat in people with HIV, but this study tested it for a different purpose — improving cognitive function in aging.
Did the cognitive improvements last after the treatment stopped?
The study included a 10-week washout period after treatment ended, but the abstract does not detail whether cognitive gains persisted through that point. The authors noted that longer treatment trials are needed to fully understand how durable these brain benefits might be.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-01900APA
Baker, Laura D; Barsness, Suzanne M; Borson, Soo; Merriam, George R; Friedman, Seth D; Craft, Suzanne; Vitiello, Michael V. (2012). Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.. Archives of neurology, 69(11), 1420-9.
MLA
Baker, Laura D, et al. "Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.." Archives of neurology, 2012.
RethinkPeptides
RethinkPeptides Research Database. "Effects of growth hormone–releasing hormone on cognitive fun..." RPEP-01900. Retrieved from https://rethinkpeptides.com/research/baker-2012-effects-of-growth-hormonereleasing
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.